{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:55:53Z","timestamp":1790207753670,"version":"4.1.0"},"reference-count":152,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2503704"],"award-info":[{"award-number":["2022YFC2503704"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["24QA2711800"],"award-info":[{"award-number":["24QA2711800"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32270814"],"award-info":[{"award-number":["32270814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82403719"],"award-info":[{"award-number":["82403719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92359301"],"award-info":[{"award-number":["92359301"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canlet.2025.217540","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:21:30Z","timestamp":1738927290000},"page":"217540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics"],"prefix":"10.1016","volume":"614","author":[{"given":"Xiaowen","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2025.217540_bib1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/00000658-192208000-00008","article-title":"Malignant neoplasms of the extrahepatic biliary ducts","volume":"76","author":"Renshaw","year":"1922","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2025.217540_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nrgastro.2011.131","article-title":"Clinical diagnosis and staging of cholangiocarcinoma","volume":"8","author":"Blechacz","year":"2011","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib3","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2025.217540_bib4","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"Ilyas","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.217540_bib5","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2025.217540_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.canlet.2025.217540_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/jamaoncol.2015.0735","article-title":"The global burden of cancer 2013","volume":"1","author":"Global Burden of Disease Cancer","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib8","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217540_bib9","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12876-022-02637-8","article-title":"The epidemiological trends of biliary tract cancers in the United States of America","volume":"22","author":"Jiang","year":"2022","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.canlet.2025.217540_bib10","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.217540_bib11","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1002\/cncr.33476","article-title":"The global, regional, and national burden of gallbladder and biliary tract cancer and its attributable risk factors in 195 countries and territories, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"127","author":"Ouyang","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib12","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Ilyas","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib13","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib14","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Pancreatic Oncology Group of the Japan Clinical Oncology, Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217540_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1200\/JCO.18.00050","article-title":"Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study","volume":"37","author":"Edeline","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.canlet.2025.217540_bib16","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/liv.14086","article-title":"Clinical presentation, diagnosis and staging of cholangiocarcinoma","volume":"39","author":"Forner","year":"2019","journal-title":"Liver Int."},{"key":"10.1016\/j.canlet.2025.217540_bib17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib18","doi-asserted-by":"crossref","first-page":"v28","DOI":"10.1093\/annonc\/mdw324","article-title":"Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"27","author":"Valle","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib19","doi-asserted-by":"crossref","first-page":"343","DOI":"10.4143\/crt.2014.308","article-title":"Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review","volume":"47","author":"Park","year":"2015","journal-title":"Cancer. Res. Treat."},{"key":"10.1016\/j.canlet.2025.217540_bib20","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/sj.bjc.6605779","article-title":"Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan","volume":"103","author":"Okusaka","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib22","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","article-title":"H. members of the, G. Pancreatic Oncology Group of the Japan Clinical Oncology, Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial","volume":"30","author":"Morizane","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib23","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/annonc\/mdz058","article-title":"Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial","volume":"30","author":"Kim","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"Ioka","year":"2023","journal-title":"J. Hepatobiliary. Pancreat. Sci."},{"key":"10.1016\/j.canlet.2025.217540_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1186\/s12885-019-6142-y","article-title":"Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer - the NIFE trial (AIO-YMO HEP-0315) an open label, non-comparative, randomized, multicenter phase II study","volume":"19","author":"Perkhofer","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.2082","article-title":"LBA10 Nal-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary tract cancer: final results of the NIFE-trial (AIO-YMO HEP-0315), a randomized phase II study of the AIO biliary tract cancer group","volume":"32","author":"Perkhofer","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib27","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib28","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.canlet.2025.217540_bib29","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.canlet.2025.217540_bib30","doi-asserted-by":"crossref","first-page":"S1462","DOI":"10.1016\/j.annonc.2022.10.114","article-title":"78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)","volume":"33","author":"Oh","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib31","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4075","article-title":"Regional subgroup analysis of the phase 3 TOPAZ-1 study of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC)","volume":"40","author":"Vogel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib32","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2025.217540_bib33","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4080","article-title":"Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma","volume":"37","author":"Silverman","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.4087","article-title":"Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH)","volume":"37","author":"Javle","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib35","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2025.217540_bib36","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1158\/1078-0432.CCR-18-0078","article-title":"Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention","volume":"24","author":"Lowery","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib37","doi-asserted-by":"crossref","first-page":"652","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib38","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib39","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2025.217540_bib41","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"Kam","year":"2021","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib42","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1200\/PO.18.00414","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients","volume":"4","author":"Cao","year":"2020","journal-title":"Juco. Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2025.217540_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms6696","article-title":"Mutational landscape of intrahepatic cholangiocarcinoma","volume":"5","author":"Zou","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217540_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.canlet.2025.217540_bib46","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib47","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib49","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib50","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2021.08.332","article-title":"53P FGFR2 fusion and\/or rearrangement profiling in Chinese patients with intrahepatic cholangiocarcinoma","volume":"32","author":"Huang","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib52","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Bahleda","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib54","article-title":"INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2025.217540_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO. Open."},{"key":"10.1016\/j.canlet.2025.217540_bib56","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1002\/cam4.5273","article-title":"Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: a phase II study","volume":"12","author":"Shi","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2025.217540_bib57","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib58","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib59","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib60","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1186\/s12885-024-12584-0","article-title":"Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial","volume":"24","author":"Park","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib61","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4121","article-title":"Efficacy and safety of erdafitinib in patients with advanced or metastatic cholangiocarcinoma and FGFR alterations: pooled analysis of RAGNAR and LUC2001 studies","volume":"42","author":"Pant","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib62","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.427","article-title":"Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2 mutations or amplifications: interim results from the phase 2 study FIDES-01","volume":"40","author":"Javle","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib64","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.434","article-title":"Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: results from phase II clinical trial","volume":"42","author":"Javle","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib65","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib66","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.4092","article-title":"Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations","volume":"39","author":"Guo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib67","article-title":"IDH inhibitors in advanced cholangiocarcinoma: another arrow in the quiver?","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer. Treat. Res. Commun."},{"key":"10.1016\/j.canlet.2025.217540_bib68","doi-asserted-by":"crossref","first-page":"751","DOI":"10.21037\/jgo.2019.03.10","article-title":"Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review","volume":"10","author":"Boscoe","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib69","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217540_bib70","doi-asserted-by":"crossref","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-12-1773","article-title":"IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives","volume":"18","author":"Yang","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib71","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S2468-1253(19)30189-X","article-title":"Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study","volume":"4","author":"Lowery","year":"2019","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib72","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1002\/cncr.32463","article-title":"Second-line chemotherapy in advanced biliary cancers: a retrospective, multicenter analysis of outcomes","volume":"125","author":"Lowery","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib73","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib74","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1158\/1078-0432.CCR-21-4462","article-title":"FDA approval summary: ivosidenib for the treatment of patients with advanced unresectable or metastatic, chemotherapy refractory cholangiocarcinoma with an IDH1 mutation","volume":"28","author":"Casak","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib75","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41698-022-00304-5","article-title":"Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma","volume":"6","author":"Cleary","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217540_bib78","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib79","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1200\/JCO.23.02010","article-title":"Trastuzumab deruxtecan in human epidermal growth factor receptor 2-expressing biliary tract cancer (HERB; NCCH1805): a multicenter, single-arm, phase II trial","volume":"42","author":"Ohba","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib80","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.4090","article-title":"Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): outcomes from DESTINY-PanTumor02 (DP-02)","volume":"42","author":"Oh","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib81","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","article-title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","volume":"24","author":"Harding","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib82","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217540_bib83","article-title":"Tucatinib and trastuzumab for previously treated HER2-positive metastatic biliary tract cancer (SGNTUC-019): a phase 2 basket study","volume":"41","author":"Nakamura","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib84","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S2468-1253(22)00335-1","article-title":"Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14)","volume":"8","author":"Lee","year":"2023","journal-title":"Lancet. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib85","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2025.217540_bib86","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.23.00434","article-title":"Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib87","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41591-023-02696-8","article-title":"Divarasib plus cetuximab in -positive colorectal cancer: a phase 1b trial","volume":"30","author":"Desai","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib88","article-title":"Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors","volume":"42","author":"Li","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib89","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRAS inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.canlet.2025.217540_bib90","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217540_bib91","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1056\/NEJMoa2105281","article-title":"Acquired resistance to KRAS(G12C) inhibition in cancer","volume":"384","author":"Awad","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib92","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","article-title":"Biliary cancer: utility of next-generation sequencing for clinical management","volume":"122","author":"Javle","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib93","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizons for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib94","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S1470-2045(20)30321-1","article-title":"Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial","volume":"21","author":"Subbiah","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib95","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","article-title":"Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial","volume":"29","author":"Subbiah","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib96","article-title":"Intrahepatic cholangiocarcinoma: genomic heterogeneity between eastern and western patients","volume":"4","author":"Cao","year":"2020","journal-title":"JCO. Precis. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib97","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib98","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib99","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1158\/1078-0432.CCR-23-0459","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib100","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1080\/13543784.2021.1896703","article-title":"Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers","volume":"30","author":"Boileve","year":"2021","journal-title":"Expert. Opin. Invest. Drugs."},{"key":"10.1016\/j.canlet.2025.217540_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO. Open."},{"key":"10.1016\/j.canlet.2025.217540_bib102","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib103","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib104","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","article-title":"Poly(ADP-ribose) polymerase inhibition: past, present and future","volume":"19","author":"Curtin","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib105","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15981","article-title":"Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells","volume":"8","author":"Schoonen","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2025.217540_bib106","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1634\/theoncologist.2016-0415","article-title":"Overall survival and clinical characteristics of BRCA-associated cholangiocarcinoma: a multicenter retrospective study","volume":"22","author":"Golan","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.canlet.2025.217540_bib107","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.4_suppl.452","article-title":"Phase II study of combination pembrolizumab and olaparib in patients with advanced cholangiocarcinoma: interim results","volume":"40","author":"Yin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib108","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e22061","article-title":"Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347)","volume":"38","author":"ali","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib109","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","author":"Drew","year":"2025","journal-title":"Nat. Rev. Drug. Discov. 24"},{"key":"10.1016\/j.canlet.2025.217540_bib110","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.bbrc.2005.03.151","article-title":"Mdmx as an essential regulator of p53 activity","volume":"331","author":"Marine","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2025.217540_bib111","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.4161\/cc.9.7.11255","article-title":"p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors","volume":"9","author":"Li","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.canlet.2025.217540_bib112","doi-asserted-by":"crossref","first-page":"254","DOI":"10.7555\/JBR.27.20130030","article-title":"The MDM2-p53 pathway revisited","volume":"27","author":"Nag","year":"2013","journal-title":"J. Biomed. Res."},{"key":"10.1016\/j.canlet.2025.217540_bib113","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase ia, first-in-human, dose-escalation study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib114","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.3095","article-title":"A phase Ia\/Ib, dose-escalation\/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors","volume":"40","author":"Yamamoto","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib115","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/cncr.31872","article-title":"A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma","volume":"125","author":"Sun","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib116","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.annonc.2020.05.018","article-title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced\/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial","volume":"31","author":"Demols","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejca.2021.11.012","article-title":"Regorafenib-avelumab combination in patients with biliary tract cancer (REGOMUNE): a single-arm, open-label, phase II trial","volume":"162","author":"Cousin","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib118","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40265-021-01489-y","article-title":"Surufatinib: first approval","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.canlet.2025.217540_bib119","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1002\/cncr.33803","article-title":"A single-arm, multicenter, open-label phase 2 trial of surufatinib in patients with unresectable or metastatic biliary tract cancer","volume":"127","author":"Xu","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2025.217540_bib120","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00432-021-03898-8","article-title":"Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial","volume":"149","author":"Cao","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib121","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00262-024-03677-7","article-title":"Efficacy and safety of surufatinib plus toripalimab, a chemotherapy-free regimen, in patients with advanced gastric\/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, or biliary tract cancer","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2025.217540_bib122","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay0152","article-title":"PTEN status determines chemosensitivity to proteasome inhibition in cholangiocarcinoma","volume":"12","author":"Jiang","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib123","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.canlet.2018.02.017","article-title":"Combination of Kras activation and PTEN deletion contributes to murine hepatopancreatic ductal malignancy","volume":"421","author":"Lin","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217540_bib124","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/path.4189","article-title":"PTEN loss and KRAS activation cooperate in murine biliary tract malignancies","volume":"230","author":"Marsh","year":"2013","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2025.217540_bib125","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2022.11.025","article-title":"PTEN deficiency facilitates exosome secretion and metastasis in cholangiocarcinoma by impairing TFEB-mediated lysosome biogenesis","volume":"164","author":"Jiang","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.217540_bib126","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1053\/j.gastro.2022.12.034","article-title":"Lysosomes promote cancer metastasis via exosome in PTEN-deficient tumors","volume":"164","author":"Zhou","year":"2023","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2025.217540_bib127","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2020.11.016","article-title":"PTEN deficiency facilitates the therapeutic vulnerability to proteasome inhibitor bortezomib in gallbladder cancer","volume":"501","author":"Jiang","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217540_bib128","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.add7464","article-title":"PTEN deficiency facilitates gemcitabine efficacy in cancer by modulating the phosphorylation of PP2Ac and DCK","volume":"15","author":"Jiang","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib129","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2025.217540_bib130","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1675","article-title":"Bortezomib in previously treated phosphatase and tension homology-deficient patients with advanced intrahepatic cholangiocarcinoma: an open-label, prospective and single-centre phase II trial","volume":"14","author":"Zeng","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib131","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Burris","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.080","article-title":"52MO A randomized phase II trial of durvalumab and tremelIMUmab with gemcitabine or gemcitabine and cisplatin compared to gemcitabine and cisplatin in treatment-na\u00efve patients with CHolangio- and gallbladdEr Carcinoma (IMMUCHEC)","volume":"33","author":"Vogel","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib133","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.475","article-title":"ZSAB-TOP: a phase 2 trial of tislelizumab (TIS) and ociperlimab (OCI) combined with gemcitabine and cisplatin (GemCis) as the first-line treatment for advanced biliary tract cancer (BTC)","volume":"42","author":"Fan","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.3_suppl.435","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: results from a randomized proof-of-concept phase II trial (IMbrave151)","volume":"42","author":"El-Khoueiry","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib135","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.4100","article-title":"A phase 2, randomized, open-label, multicenter study of sintilimab and anlotinib in combination with gemcitabine plus cisplatin (GemCis) as first-line therapy in patients (pts) with advanced biliary tract cancer (BTC): SAGC","volume":"40","author":"Jingjing","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib136","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13030558","article-title":"PD-L1, TMB, MSI, and other predictors of response to immune checkpoint inhibitors in biliary tract cancer","volume":"13","author":"Rizzo","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2025.217540_bib137","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib138","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1038\/onc.2012.617","article-title":"Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies","volume":"32","author":"Sia","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2025.217540_bib139","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1158\/1078-0432.CCR-14-3296","article-title":"Molecular pathogenesis and targeted therapies for intrahepatic cholangiocarcinoma","volume":"22","author":"Moeini","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2025.217540_bib140","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib141","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/tgh.2018.07.02","article-title":"Precision medicine in cholangiocarcinoma","volume":"3","author":"Pellino","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.canlet.2025.217540_bib142","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib143","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR blockade reverts resistance to KRAS(G12C) inhibition in colorectal cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217540_bib144","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-018-0024-8","article-title":"Mutant KRAS-driven cancers depend on PTPN11\/SHP2 phosphatase","volume":"24","author":"Ruess","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2025.217540_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216264","article-title":"MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells","volume":"567","author":"Hondo","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2025.217540_bib146","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaw9450","article-title":"KRAS(G12C) inhibition produces a driver-limited state revealing collateral dependencies","volume":"12","author":"Lou","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.canlet.2025.217540_bib147","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41586-019-1884-x","article-title":"Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition","volume":"577","author":"Xue","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2025.217540_bib148","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pharmrev.123.001026","article-title":"MDM2 inhibitors for cancer therapy: the past, present, and future","volume":"76","author":"Wang","year":"2024","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.canlet.2025.217540_bib149","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrclinonc.2017.151","article-title":"Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others","volume":"15","author":"Sabapathy","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2025.217540_bib150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/modpathol.2011.133","article-title":"The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas","volume":"25","author":"Lee","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.canlet.2025.217540_bib151","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1006\/jsre.2001.6194","article-title":"Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome","volume":"100","author":"Bold","year":"2001","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.canlet.2025.217540_bib152","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-024-01896-z","article-title":"Synergistic induction of mitotic pyroptosis and tumor remission by inhibiting proteasome and WEE family kinases","volume":"9","author":"Chen","year":"2024","journal-title":"Signal. Transduct. Target. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525001041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:57:21Z","timestamp":1760741841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525001041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":152,"alternative-id":["S0304383525001041"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217540","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status and prospects of targeted therapy for cholangiocarcinoma based on molecular characteristics","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217540"}}